A61K 40/42
Cancer antigens
A61K40/42 (Cancer antigens) appears on 5,246 US grants and 11,979 published applications in this corpus.
Search patents in A61K- Granted patents
- 5,246
- Published applications
- 11,979
- Assignees
- 2,690
- Inventors
- 14,448
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 6 | 0 |
| 1994 | 7 | 0 |
| 1995 | 4 | 0 |
| 1996 | 6 | 0 |
| 1997 | 11 | 0 |
| 1998 | 31 | 0 |
| 1999 | 17 | 0 |
| 2000 | 22 | 0 |
| 2001 | 25 | 13 |
| 2002 | 47 | 119 |
| 2003 | 33 | 149 |
| 2004 | 30 | 142 |
| 2005 | 23 | 106 |
| 2006 | 46 | 110 |
| 2007 | 20 | 81 |
| 2008 | 48 | 137 |
| 2009 | 45 | 118 |
| 2010 | 76 | 165 |
| 2011 | 76 | 168 |
| 2012 | 76 | 137 |
| 2013 | 96 | 158 |
| 2014 | 100 | 206 |
| 2015 | 128 | 187 |
| 2016 | 138 | 280 |
| 2017 | 142 | 410 |
| 2018 | 204 | 553 |
| 2019 | 295 | 790 |
| 2020 | 445 | 1000 |
| 2021 | 455 | 1173 |
| 2022 | 478 | 1333 |
| 2023 | 471 | 1201 |
| 2024 | 559 | 1343 |
| 2025 | 635 | 1074 |
| 2026 | 436 | 826 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 40/4202Receptors, cell surface antigens or cell surface determinants2,108
- A61K 40/4271Melanoma antigens405
- A61K 40/428Undefined tumor antigens383
- A61K 40/4267Cancer testis antigens297
- A61K 40/4244Enzymes289
- A61K 40/4254Adhesion molecules259
- A61K 40/4256Tumor associated carbohydrates202
- A61K 40/4242Transcription factors182
All 19 subgroupsShow fewer
- A61K 40/4231Cytokines157
- A61K 40/4274Prostate associated antigens e.g. prostate stem cell antigen [psca]150
- A61K 40/4264From embryonic or fetal origin136
- A61K 40/4238Regulators of development84
- A61K 40/4201Neoantigens74
- A61K 40/4261Proteoglycans63
- A61K 40/4262Heat shock proteins54
- A61K 40/4225Growth factors42
- A61K 40/4277Fusion proteins originating from gene translocation in cancer cells8
- A61K 40/4237Hormones7
- A61K 40/4263Tumor rejection antigen precursor [trap]0
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Extracellular vesicles for the delivery of payloads to eukaryotic cells8 Oct 2026US 2026/0306416 A1Alaya.bio Inc.
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Methods of sensitizing tumors to treatment with immune checkpoint inhibitors8 Oct 2026US 2026/0306658 A1University of Florida Research Foundation, Inc.
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells384US 6,905,681 B1Genetics Institute, Inc. · 2005
- Simultaneous stimulation and concentration of cells383US 6,905,874 B2XCYTE Therapies, Inc. · 2005